Ryan & Maniskas, LLP Announces Investigation of MiMedx Group, Inc.
WAYNE, Pa., Sept. 5, 2013 /PRNewswire/ -- Ryan & Maniskas, LLP announces that it is investigating potential claims against MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG) who purchased MiMedx common stock between October 30, 2012 and September 4, 2013 (the "Class Period").
The investigation concerns whether MiMedx and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On September 4, 2013, MiMedx confirmed that it is in receipt of an "Untitled Letter" from the Food and Drug Administration ("FDA"). The letter stated MiMedx's Surgical Biologics unit violated the Public Health Service Act by unlawfully manufacturing drugs at one of its plants, and thereby marketed unapproved biologics products.
On this news, shares of MiMedx fell $2.21 per share to more than 36.49% to close at $3.85 on September 4, 2013.
For more information regarding this, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at email@example.com or visit: www.rmclasslaw.com/cases/mdxg. For more information about class action cases in general or to learn more about Ryan & Maniskas, LLP, please visit our website: www.rmclasslaw.com.
Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.
SOURCE Ryan & Maniskas, LLP
More by this Source
Ryan & Maniskas, LLP Files Class Action Lawsuit Against PhotoMedex, Inc.
Dec 06, 2013, 18:00 ET
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Hertz Global Holdings, Inc.
Dec 04, 2013, 19:15 ET
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against DFC Global Corp.
Dec 03, 2013, 18:15 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.